Clinical Trial Update: Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy. [Phase 3]

View source ↗

Summary

The Phase 3 open-label trial of Seletracetam in refractory epilepsy has been withdrawn, according to sponsor UCB Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Seletracetam (Seletracetam)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: WITHDRAWN